Edition:
India

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

13.87USD
22 Jun 2018
Change (% chg)

$-0.21 (-1.49%)
Prev Close
$14.08
Open
$14.11
Day's High
$14.17
Day's Low
$13.68
Volume
179,028
Avg. Vol
50,564
52-wk High
$19.50
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

Oxford Immunotec Announces Preliminary Revenue For Q4
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Oxford Immunotec Global Plc ::FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S.OXFORD IMMUNOTEC ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER AND FULL YEAR 2017.SEES FY 2017 REVENUE $103 MILLION TO $103.5 MILLION.SEES Q4 2017 REVENUE $24.9 MILLION TO $25.4 MILLION.Q4 REVENUE VIEW $26.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit
Saturday, 16 Dec 2017 

Dec 15 (Reuters) - Oxford Immunotec Global Plc ::OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL - UNDER TERMS OF AGREEMENT, ALL PENDING CLAIMS BETWEEN OXFORD, QIAGEN AND CO-DEFENDANTS HAVE BEEN RESOLVED.OXFORD IMMUNOTEC GLOBAL - CO GRANTED QIAGEN ROYALTY-FREE, NON-EXCLUSIVE LICENSE THAT EXTENDS TO ALL CURRENT AND FUTURE CUSTOMERS OF QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - PATENT INFRINGEMENT IS IN RELATION TO QIAGEN'S QUANTIFERON-TB GOLD AND QUANTIFERON-TB GOLD PLUS PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - OXFORD GRANTED QIAGEN A ROYALTY-FREE, NON-EXCLUSIVE LICENSE IN EXCHANGE FOR A ONE-TIME, LUMP-SUM PAYMENT OF $27.5 MILLION.  Full Article

Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​
Wednesday, 22 Nov 2017 

Nov 21 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​.Oxford Immunotec Global says ‍second amendment extends term of agreement until December 31, 2023 & establishes pricing - SEC Filing​.  Full Article

Oxford Immunotec Global Q3 loss per share $0.70
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec reports third quarter 2017 financial results.Q3 loss per share $0.70.Sees Q4 2017 revenue $25.4 million to $26.4 million.Q3 revenue $30.4 million versus I/B/E/S view $30 million.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $103.5 million to $104.5 million.FY2017 revenue view $104.6 million -- Thomson Reuters I/B/E/S.  Full Article

Oxford Immunotec reports Q3 loss per share $0.18
Tuesday, 1 Nov 2016 

Oxford Immunotec Global Plc - : Expect to have over $50 million in cash at end of 2016 . FY2016 revenue view $83.7 million -- Thomson Reuters I/B/E/S . Oxford Immunotec reports third quarter 2016 financial results . Q3 loss per share $0.18 . Sees Q4 2016 revenue $22.6 million to $23.4 million . Q3 revenue $26.1 million versus I/B/E/S view $24.8 million . Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Sees FY 2016 revenue up 35 to 37 percent .Sees FY 2016 revenue $85 million to $85.8 million.  Full Article

Oxford Immunotec announces closing of $40 million in debt financing
Wednesday, 5 Oct 2016 

Oxford Immunotec Global Plc : Oxford Immunotec announces closing of $40 million in debt financing . Says entered into an agreement with Midcap Financial that provides company with $40 million in debt financing . Says $40 million comprised of both a term loan and a revolving line of credit .Term loan of $30 million, revolving line of credit of up to $10 million both mature five years from closing.  Full Article

Oxford Immunotec Q2 loss per share $0.29
Tuesday, 2 Aug 2016 

Oxford Immunotec Global Plc : Q2 loss per share $0.29 . Sees fy 2016 revenue $82.5 million to $84.5 million . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Oxford Immunotec reports second quarter 2016 financial results . Sees Q3 2016 revenue $24.2 million to $25 million . Q2 revenue $19.2 million versus I/B/E/S view $18.1 million . FY 2016 revenue view $79.6 million -- Thomson Reuters I/B/E/S .Q3 revenue view $22.7 million -- Thomson Reuters I/B/E/S.  Full Article